Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Cancer Ther
2013 Jul 01;127:1180-9. doi: 10.1158/1535-7163.MCT-12-1176-T.
Show Gene links
Show Anatomy links
Identification and characterization of a small-molecule inhibitor of Wnt signaling in glioblastoma cells.
De Robertis A
,
Valensin S
,
Rossi M
,
Tunici P
,
Verani M
,
De Rosa A
,
Giordano C
,
Varrone M
,
Nencini A
,
Pratelli C
,
Benicchi T
,
Bakker A
,
Hill J
,
Sangthongpitag K
,
Pendharkar V
,
Liu B
,
Ng FM
,
Then SW
,
Jing Tai S
,
Cheong SM
,
He X
,
Caricasole A
,
Salerno M
.
???displayArticle.abstract???
Glioblastoma multiforme (GBM) is the most common and prognostically unfavorable form of brain tumor. The aggressive and highly invasive phenotype of these tumors makes them among the most anatomically damaging human cancers with a median survival of less than 1 year. Although canonical Wnt pathway activation in cancers has been historically linked to the presence of mutations involving key components of the pathway (APC, β-catenin, or Axin proteins), an increasing number of studies suggest that elevated Wnt signaling in GBM is initiated by several alternative mechanisms that are involved in different steps of the disease. Therefore, inhibition of Wnt signaling may represent a therapeutically relevant approach for GBM treatment. After the selection of a GBM cell model responsive to Wnt inhibition, we set out to develop a screening approach for the identification of compounds capable of modulating canonical Wnt signaling and associated proliferative responses in GBM cells. Here, we show that the small molecule SEN461 inhibits the canonical Wnt signaling pathway in GBM cells, with relevant effects at both molecular and phenotypic levels in vitro and in vivo. These include SEN461-induced Axin stabilization, increased β-catenin phosphorylation/degradation, and inhibition of anchorage-independent growth of human GBM cell lines and patient-derived primary tumor cells in vitro. Moreover, in vivo administration of SEN461 antagonized Wnt signaling in Xenopus embryos and reduced tumor growth in a GBM xenograft model. These data represent the first demonstration that small-molecule-mediated inhibition of Wnt signaling may be a potential approach for GBM therapeutics.
Augustin,
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis.
2012, Pubmed
Augustin,
The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis.
2012,
Pubmed
Bafico,
An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells.
2004,
Pubmed
Barker,
Mining the Wnt pathway for cancer therapeutics.
2006,
Pubmed
Benhaj,
Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
2006,
Pubmed
Cancer Genome Atlas Research Network,
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
2008,
Pubmed
Chen,
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
2009,
Pubmed
Clevers,
Wnt/beta-catenin signaling in development and disease.
2006,
Pubmed
Harland,
Formation and function of Spemann's organizer.
1997,
Pubmed
Holland,
Glioblastoma multiforme: the terminator.
2000,
Pubmed
Huang,
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.
2009,
Pubmed
Jin,
Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation.
2011,
Pubmed
Katoh,
Regulation of WNT3 and WNT3A mRNAs in human cancer cell lines NT2, MCF-7, and MKN45.
2002,
Pubmed
Kim,
The protein stability of Axin, a negative regulator of Wnt signaling, is regulated by Smad ubiquitination regulatory factor 2 (Smurf2).
2010,
Pubmed
Kim,
SUMOylation target sites at the C terminus protect Axin from ubiquitination and confer protein stability.
2008,
Pubmed
Kolligs,
ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation.
2002,
Pubmed
Kruse,
Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.
1992,
Pubmed
Kumar,
Metastasis-associated protein 1 short form stimulates Wnt1 pathway in mammary epithelial and cancer cells.
2010,
Pubmed
Lambiv,
The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence.
2011,
Pubmed
Lui,
The ubiquitin-specific protease USP34 regulates axin stability and Wnt/β-catenin signaling.
2011,
Pubmed
MacDonald,
Wnt/beta-catenin signaling: components, mechanisms, and diseases.
2009,
Pubmed
,
Xenbase
Moon,
WNT and beta-catenin signalling: diseases and therapies.
2004,
Pubmed
Morin,
Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.
1997,
Pubmed
Nakashima,
Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer.
2010,
Pubmed
Nusse,
Wnt genes.
1992,
Pubmed
Nusse,
Wnt signaling in disease and in development.
2005,
Pubmed
Oloumi,
Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells.
2006,
Pubmed
Pu,
Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth.
2009,
Pubmed
Pulvirenti,
Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas.
2011,
Pubmed
Rajan,
Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression.
2011,
Pubmed
Satoh,
AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1.
2000,
Pubmed
Semënov,
Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.
2001,
Pubmed
,
Xenbase
Semënov,
SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
2005,
Pubmed
,
Xenbase
Uematsu,
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression.
2003,
Pubmed
van de Wetering,
The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.
2002,
Pubmed
Verras,
Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells.
2004,
Pubmed
Waaler,
A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice.
2012,
Pubmed
,
Xenbase
Yang,
FZD7 has a critical role in cell proliferation in triple negative breast cancer.
2011,
Pubmed
Zhang,
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis.
2011,
Pubmed
Zhang,
Axin induces cell death and reduces cell proliferation in astrocytoma by activating the p53 pathway.
2009,
Pubmed
Zheng,
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.
2010,
Pubmed
Zhu,
The molecular and genetic basis of neurological tumours.
2002,
Pubmed
